Weiting Zhang1, Teri N. Kreisl1, Jeff Solomon2, Richard C. Reynolds3, Danial R. Glen3, Robert W. Cox3, Howard A. Fine1, John A. Butman4
1Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA; 2Medical Numerics, Inc., Germantown, MD, USA; 3National Institute of Mental Health, NIH, USA; 4Radiology and Imaging Sciences, Clinial Center, NIH, USA
DCE-MRI was used to monitor the acute effects of Bevacizumab on physiologic measures of tumor vascularity, such as blood brain barrier permeability, represented as Ktrans. In addition, we relate these to progression free survival (PFS) and to overall survival (OS). Bevacizumab dramatically reduces Ktrans (46%) and enhancing tumor volume (39%) in recurrent GBMs within 96-hour of a single dose. However, tumors in which Bevacizumab resulted in larger decreases in Ktrans did not demonstrate an improved survival over those with smaller reductions in Ktrans. GBMs with larger baseline enhancing tumor volume and greater baseline Ktrans both predicted poorer PFS and OS.